Inactive

U.S. Army Medical Materiel Development Activity (USAMMDA) Warfighter Protection and Acute Care Project (WPAC) has a requirement for development of a drug that would be useful in a pre-hospital setting... U.S. Army Medical Materiel Development Activity (USAMMDA) Warfighter Protection and Acute Care Project (WPAC) has a requirement for development of a drug that would be useful in a pre-hospital setting for treatment of hemorrhagic shock in humans. Wounded Warfighters deserve the best chance at survival that we can give them. The desired benefits of the drug are that its administration would increase the probability of survival, reduce the need for other treatment products, and reduce the need for prompt medical evacuation. The following characteristics are considered desirable: (1) The drug would most likely be administered promptly after injury, before blood or blood components are administered; however, a drug that would be administered as a pre-treatment, prior to injury, would also be of interest. (2) The drug would be administered in a low volume, perhaps 5 to 20 milliliters, to minimize the burden of transporting it and administering it. (3) The drug would be stable (retain its effectiveness) for at least one year over a broad temperature range. (4) The drug would be amenable to administration by several routes, such as oral, intravenous, intraosseous, inhalation, and intramuscular.